A Low Transition Temperature Mixture-based viscosupplementation complemented with celecoxib for osteoarthritis treatment.
Low Transition Temperature Mixtures
anti-inflammatory
celecoxib
hyaluronic acid
osteoarthritis
viscosupplementation
Journal
International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127
Informations de publication
Date de publication:
04 Apr 2024
04 Apr 2024
Historique:
received:
12
01
2024
revised:
02
04
2024
accepted:
03
04
2024
medline:
7
4
2024
pubmed:
7
4
2024
entrez:
6
4
2024
Statut:
aheadofprint
Résumé
Viscosupplementation consists of hyaluronic acid (HA) intra-articular injections, commonly applied for osteoarthritis treatment while non-steroidal anti-inflammatory drugs (NSAID) are widely administered for pain relief. Here, HA and NSAID (celecoxib) were combined in a formulation based on a low transition temperature mixture (LTTM) of glycerol:sorbitol, reported to increase celecoxib's solubility, thus rendering a potential alternative viscosupplement envisioning enhanced therapeutic efficiency. The inclusion of glucosamine, a cartilage precursor, was also studied. The developed formulations were assessed in terms of rheological properties, crucial for viscosupplementation: the parameters of crossover frequency, storage (G') and loss (G'') moduli, zero-shear-rate viscosity, stable viscosity across temperatures and shear thinning behaviour, support viscoelastic properties suitable for viscosupplementation. Additionally, the gels biocompatibility was confirmed in chondrogenic cells (ATDC5). Regarding drug release studies, high and low clearance scenarios demonstrated an increased celecoxib (CEX) release from the gel (6 to 73-fold), compared to dissolution in PBS. The low clearance setup presented the highest and most sustained CEX release, highlighting the importance of the gel structure in CEX delivery. NMR stability studies over time demonstrated the LTTM+HA+CEX (GHA+CEX) gel as viable candidate for further in vivo evaluation. In sum, the features of GHA+CEX support its potential use as alternative viscosupplement.
Identifiants
pubmed: 38582102
pii: S0378-5173(24)00322-3
doi: 10.1016/j.ijpharm.2024.124088
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
124088Informations de copyright
Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ana Rita C. Duarte reports financial support was provided by European Commission. Ana Roda reports financial support was provided by Foundation for Science and Technology. Ana Roda reports financial support was provided by Government of Portuguese Republic Ministry of Science Technology and Higher Education. Ana Rita C. Duarte, Ana Roda, Alexandre Paiva has patent pending to Faculdade de Ciências e Tecnologia da Universidade Nova de Lisboa. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.